Displaying drugs 10376 - 10400 of 10844 in total
Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid
A nucleoside monophosphate sugar which donates N-acetylneuraminic acid to the terminal sugar of a ganglioside or glycoprotein. [PubChem]
Experimental
Matched Description: … A nucleoside monophosphate sugar which donates N-acetylneuraminic acid to the terminal sugar of a ganglioside …
Hexoprenaline
Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.
Experimental
Withdrawn
Matched Description: … Hexoprenaline is a stimulant of beta 2 adrenergic receptors. …
Matched Salts cas: … 32266-10-7 …
Matched Salts cas: … 32266-10-7 …
LTX-109
LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.
Investigational
Matched Description: … LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive …
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
Matched Description: … HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of …
Alphameprodine
Alphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. The stereoisomer betameprodine is similarly classified, however alphameprodine is more widely used (both are referred to as Meprodine). Alphameprodine is a structural analogue of meperidine. It exerts physiological effects characteristic of...
Experimental
Illicit
Matched Description: … Alphameprodine is a structural analogue of meperidine. ... an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of ... It exerts physiological effects characteristic of opioids, such as analgesia, euphoria and sedation, …
Ertumaxomab
Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).
Investigational
Matched Description: … Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional …
SEphB4-HSA
SEphB4-HSA is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … SEphB4-HSA is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein ... With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors). …
Methapyrilene
Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Withdrawn
Matched Description: … Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. ... Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979. …
Teceleukin
Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).
Investigational
Matched Description: … Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes ... MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic …
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
Matched Description: … Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF …
Clesrovimab
Clesrovimab is under investigation in clinical trial NCT04938830 (Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)).
Investigational
Matched Description: … Clesrovimab is under investigation in clinical trial NCT04938830 (Clesrovimab (MK-1654) in Infants and …
MVA-BN-brachyury-TRICOM vaccine
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1...
Investigational
Matched Description: … It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN ... encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of ... MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of …
Gefarnate
Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.
Investigational
Matched Description: … Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and …
Brilacidin
Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.
Investigational
Matched Description: … Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and …
Tinlorafenib
Tinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of BRAF V600 mutations.
Investigational
Matched Description: … Tinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of …
QL1706
QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.
Investigational
Matched Description: … QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 …
Allopurinol riboside
Allopurinol riboside is a nucleoside analogue of allopurinol with a beta-D-ribofuranosyl moiety at the 1-position.
Investigational
Matched Description: … Allopurinol riboside is a nucleoside analogue of [allopurinol] with a beta-D-ribofuranosyl moiety at …
PMC-403
PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.
Investigational
Matched Description: … PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary …
OptPA
Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.
Investigational
Matched Description: … Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity …
Nendratareotide uzatansine
Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.
Investigational
Matched Description: … Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated …
Avoplacel
Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational
Matched Description: … Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation …
Fosgemcitabine palabenamide
NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
Investigational
Matched Description: … NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic …
DNL343
DNL343 is under investigation in clinical trial NCT05842941 (HEALEY ALS Platform Trial - Regimen G DNL343).
Investigational
Matched Description: … DNL343 is under investigation in clinical trial NCT05842941 (HEALEY ALS Platform Trial - Regimen G DNL343 …
Oleandomycin
Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.
Vet approved
Matched Description: … It is synthesized from strains of _Streptomyces antibioticus_. …
Lenomorelin
Lenomorelin has been investigated for the treatment and basic science of Cancer, Alcoholism, Metabolism, Hypopituitarism, and Frailty Syndrome, among others.
Investigational
Matched Description: … Lenomorelin has been investigated for the treatment and basic science of Cancer, Alcoholism, Metabolism …
Displaying drugs 10376 - 10400 of 10844 in total